EPO (Erythropoietin)Erythropoiesis GlycoproteinSafety Rating 3/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors
Overview
About EPO
Mechanism of action
Endogenous glycoprotein hormone; binds EPO receptor on erythroid progenitors; stimulates red blood cell production; increases oxygen-carrying capacity; also neuroprotective (via IRR).
Safety profile
Polycythemia, thromboembolic events (DVT, stroke, PE — potentially fatal), hypertension, pure red cell aplasia, headache. Significant cardiovascular risk at high doses. · Safe ONLY in its monitored clinical indication (anemia, hematology-supervised). In non-anemic / endurance / performance use it raises hematocrit and carries serious thromboembolic risk — stroke, MI, pulmonary embolism, sudden death; historically linked to a cluster of endurance-athlete fatalities. Black-box warning in oncology. Rated low because the relevant real-world use here is high-risk and unmonitored.
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops EPO below your target.
Related pages
More on EPO
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Erythropoietin is the master regulator of red blood cell production; it signals through a homodimeric receptor to activate JAK2/STAT5, PI3K, and Ras/MAPK pathways in erythroid progenitors, driving their survival, proliferation, and terminal differentiation into hemoglobin-producing reticulocytes.
- A Phase III RCT in breast cancer patients receiving chemotherapy showed EPO completely prevented hemoglobin drops below 10 g/dL in the treatment arm (0% vs. 52% in controls), establishing erythropoiesis-stimulating agents (ESAs) as standard supportive care for chemotherapy-induced anemia.